Debaditya Bhattacharya

Debaditya Bhattacharya is the Vice President of Analytical Development at ElevateBio. In his current role, Deb is responsible for the CMC analytical development, strategy, and testing operations for Lentiviral vector, AAV, gene and cell therapy drug products, RNA based therapeutics, plus other modalities. Prior to ElevateBio, Deb has held CMC Process and Analytical leadership positions at CRISPR Therapeutics and bluebird bio. At CRIPSR Therapeutics, Deb's team was responsible for the development and progression of several CRISPR-editing based Immuno-Oncology cell therapy products across different stages of clinical development. At bluebird bio, Deb and his team accomplished a variety of deliverables towards the development of ZYNTEGLO™ and Lentiviral vector for ABECMA™. Prior to bluebird bio, Deb worked at Aura Biosciences where he helped develop their virus-like particles (VLP) based delivery platform technology. Additionally, he focused on the product development of a novel virus-like drug conjugates (VDCs) therapy towards the IND filing for a first-in-class treatment for ocular melanoma. Deb has a Ph.D. in Molecular Microbiology from Tufts University, Boston. Through his experiences in industry, Deb has worked in all phases of clinical development from pre-IND to marketing application (BLA and MAA) and remains interested in different aspects of drug development for gene and cell therapies.